Literature DB >> 28451869

Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis.

Kyeong Min Son1, Sung Yeon Lee2, Young Il Seo2, Ji-Eun Choi3, Hyun Ah Kim4,5.   

Abstract

We investigated the contributions made by the subjective components of the Disease Activity Score 28 (DAS28) to the treatment response of rheumatoid arthritis (RA). In addition, factors associated with poor response to treatment at 6 months, despite normalization of objective measures, were examined. A total of 426 newly diagnosed RA patients were included. The DAS28-P score (the subjective components of the DAS28 relative to the total components) was calculated as DAS28-P = 0.56 ∗ sqrt(TJC28) + 0.014 ∗ (VAS-GH) /0.56 ∗ sqrt(TJC28) + 0.28 ∗ sqrt(SJC28) + 0.7 ∗ In(erythrocyte sedimentation rate (ESR)) + 0.014 ∗ (VAS-GH). The European League Against Rheumatism (EULAR) response was assessed after 6 months of treatment. Of those who failed to attain good EULAR responses, those for whom the objective measures (the ESR, the C-reactive protein level, and swollen joints) were normalized were defined as having failed treatment because of subjective measures. The median (IQR) DAS28 score at baseline was 4.8 (4.04-5.49) and that after 6 months of treatment 3.21 (2.41-3.95). The DAS28-P score fell significantly from baseline to 6 months in good (0.43 versus 0.28, p < 0.001) and moderate responders (0.44 versus 0.4, p = 0.003), but not in non-responders (0.43 versus 0.45, p = 0.727). Younger age, a lower DAS28 score, and a lower DAS28-P score at baseline were related to a good EULAR response. Subjects who failed to respond because of subjective measures tended to have higher DAS28-P scores at baseline. We found that RA patients with high DAS28-P scores, reflecting subjective measures, were less likely to achieve good EULAR responses 6 months after treatment initiation and tended not to be classified as good responders despite normalization of objective measures.

Entities:  

Keywords:  DAS28; DAS28-P; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28451869     DOI: 10.1007/s10067-017-3628-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  20 in total

Review 1.  Mechanisms, impact and management of pain in rheumatoid arthritis.

Authors:  David A Walsh; Daniel F McWilliams
Journal:  Nat Rev Rheumatol       Date:  2014-05-27       Impact factor: 20.543

2.  The Disease Activity Score and the EULAR response criteria.

Authors:  J Fransen; P L C M van Riel
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  Non-nociceptive pain in rheumatoid arthritis is frequent and affects disease activity estimation: cross-sectional data from the FRAME study.

Authors:  A W Christensen; S Rifbjerg-Madsen; R Christensen; L Dreyer; H Tillingsøe; S Seven; M Boesen; K Ellegaard; H Bliddal; B Danneskiold-Samsøe; K Amris
Journal:  Scand J Rheumatol       Date:  2016-03-18       Impact factor: 3.641

5.  The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis.

Authors:  Richard Charles John Campbell; Michael Batley; Anthony Hammond; Fowzia Ibrahim; Gabrielle Kingsley; David L Scott
Journal:  Clin Rheumatol       Date:  2011-11-29       Impact factor: 2.980

6.  Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis.

Authors:  Maud S Jurgens; Cécile L Overman; Johannes W G Jacobs; Rinie Geenen; Bart V J Cuppen; Anne C A Marijnissen; Johannes W J Bijlsma; Paco M J Welsing; Floris P J G Lafeber; Jacob M van Laar
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

7.  Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.

Authors:  Katerina Chatzidionysiou; Johan Askling; Jonas Eriksson; Lars Erik Kristensen; Ronald van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2014-01-15       Impact factor: 19.103

8.  Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years.

Authors:  Maria L E Andersson; Björn Svensson; Stefan Bergman
Journal:  J Rheumatol       Date:  2013-11-01       Impact factor: 4.666

9.  Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis.

Authors:  Lis Cordingley; Rita Prajapati; Darren Plant; Deborah Maskell; Catharine Morgan; Faisal R Ali; Ann W Morgan; Anthony G Wilson; John D Isaacs; Anne Barton
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-06       Impact factor: 4.794

10.  A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis.

Authors:  Nalinie Joharatnam; Daniel F McWilliams; Deborah Wilson; Maggie Wheeler; Ira Pande; David A Walsh
Journal:  Arthritis Res Ther       Date:  2015-01-20       Impact factor: 5.156

View more
  2 in total

1.  The effect of concomitant hand osteoarthritis on pain and disease activity in patients with rheumatoid arthritis.

Authors:  Emmanuel Ruiz-Medrano; Hector Fabricio Espinosa-Ortega; Cesar Alejandro Arce-Salinas
Journal:  Clin Rheumatol       Date:  2019-05-10       Impact factor: 2.980

2.  Association of body composition with disease activity and disability in rheumatoid arthritis.

Authors:  Kyeong Min Son; Seong Hun Kang; Young Il Seo; Hyun Ah Kim
Journal:  Korean J Intern Med       Date:  2020-05-15       Impact factor: 2.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.